Skip to content
NewsBlazeIN – Lifestyle
Author:
Telix Pharmaceuticals Limited
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
July 21, 2026
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
July 20, 2026
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
July 20, 2026
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
July 15, 2026
FDA Alignment to Advance ProstACT Global Phase 3 Trial
July 1, 2026
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
June 22, 2026
Telix and United Imaging Announce Strategic Theranostics Collaboration
June 2, 2026
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
June 1, 2026
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
May 27, 2026
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
May 18, 2026
1
2
3
Next Page
→